Split or Whole Liver Transplantation? A… | Clinical Trial

Key information

Conditions

Zhejiang University Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Sex eligibility

All sexes

Study type

Observational

Primary location

Xiao Xu

Hangzhou, China

About this study

The primary objective of this study was to assess the safety and feasibility of split liver transplantation(SLT) for adult hepatocellular carcinoma (HCC) patients, while comparing the prognostic disparities between adult SLT and WLT also .

Liver transplantation (LT) is an effective treatment for end-stage liver disease. As a traditional marginal donor liver, the application of SLT in pediatric patients is successful.However, its application in adult liver transplantation, especially in HCC patients, remains controversial.

This retrospective study analyze outcomes among adults who underwent SLT and whole liver transplantation (WLT) at two centers from January 2018 to August 2022. A 1:1 propensity score matching (PSM) analysis was performed based on important donor and recipient variables. Baseline characteristics and postoperative outcomes of the above recipients were analyzed and compared. Statistical significance was determined using a two-sided p-value threshold of less than 0.05.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

≥ 18 years old
Received a liver transplantation between 2018 and 2022 (3) Liver transplantation was performed by SLT or WLT

Exclusion criteria

Re-LT
Multiorgan transplantation
Survival≤one week after LT
Incomplete data

Treatment and study plan

No intervention factor

Other

No intervention factor

Primary outcomes

Postoperative complications were evaluated by postoperative imaging reports and serological indicators

Time frame: Jan.1 2018-Dec.31 2022

Including rejection, emerging metabolic diseases, infections
The survival rate of each group was evaluated by follow-up survey and K-M curve

Time frame: Jan.1 2018-Dec.31 2022

Including overall survival rate and/or tumor free survival rate

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Registry information

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Apr 11, 2024
Registry last updated: Apr 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting